EP4662311A2 — Reversir molecules and methods of use thereof
Assigned to Alnylam Pharmaceuticals Inc · Expires 2025-12-17 · 0y expired
What this patent protects
The present invention provides REVERSIR compounds which inhibit the RNAi interference activity of dsRNA agents comprising a thermally destabilizing nucleotide modification in the antisense strand, and methods of use thereof.
USPTO Abstract
The present invention provides REVERSIR compounds which inhibit the RNAi interference activity of dsRNA agents comprising a thermally destabilizing nucleotide modification in the antisense strand, and methods of use thereof.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.